155 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating … ) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform … statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial … ) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions
6-K
EX-99.1
ALVO
Alvotech
30 Apr 24
Current report (foreign)
8:00am
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating … ) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions
6-K
EX-99.1
ALVO
Alvotech
25 Apr 24
Current report (foreign)
12:36pm
statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act … products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation
6-K
EX-99.1
sdcfb0px
19 Apr 24
Current report (foreign)
8:05am
6-K
EX-99.1
jo9 9iqosye
16 Apr 24
Current report (foreign)
6:30pm
6-K
EX-99.1
37g4p
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
01fcxlv q3n
1 Mar 24
Alvotech Appoints Interim Chief Quality Officer
12:16pm
6-K
EX-99.1
86e81y 6r
26 Feb 24
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
7:00am
6-K
EX-99.1
ltoagmdrsmr9x9l423t
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
aije1f4m1zgc5dj0ula
15 Feb 24
Current report (foreign)
4:00pm
6-K
EX-99.1
1845k6
29 Jan 24
Current report (foreign)
7:00am
6-K
EX-99.1
6dcrl
19 Jan 24
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
4:00pm
6-K
EX-99.1
xzr8eau k2
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
1wg8ds mu1
3 Jan 24
Current report (foreign)
2:28pm
6-K/A
EX-99.1
5bmyc4x530t8x9u08o
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
eybq5iqpudyxh
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
o3wllm1jtietz6kp qhs
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am